^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TRX-221

i
Other names: TRX-221
Company:
Therapex
Drug class:
EGFR inhibitor, EGFR C797S inhibitor
Related drugs:
5ms
Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
TRX-221
11ms
New P1/2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
TRX-221
over1year
TRX-221, a novel 4th-generation EGFR inhibitor for overcoming C797S mutation-mediated acquired resistance in NSCLC (AACR 2023)
With favorable DMPK profiles, once-daily oral dosing of TRX-221 induced strong anti-tumor effects in a dose-dependent manner in a variety of osimertinib-resistant CDX and PDX models. As a reversible, selective, and broad-spectrum 4th-generation EGFR-TKI, TRX-221 is currently undergoing IND-enabling studies and shows strong potential as a therapeutic solution to treat advanced NSCLC patients harboring EGFR mutations.
Preclinical
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR wild-type • EGFR overexpression • EGFR C797S
|
Tagrisso (osimertinib) • TRX-221